Navigation Links
Watson Pharmaceuticals and Arrow Group Receive FTC Second Request
Date:8/6/2009

MORRISTOWN, N.J., Aug. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that it has received a request for additional information from the Federal Trade Commission ("FTC") in connection with Watson's pending acquisition of privately held Arrow Group. The information request was issued under notification requirements of the Hart.Scott.Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"). The effect of the second request is to extend the waiting period imposed by the HSR Act until 30 days after Watson and Arrow Group have substantially complied with the request, unless that period is extended voluntarily by the parties or terminated sooner by the FTC. Watson intends to cooperate fully with the FTC's review and continues to expect the transaction to close in the second half of 2009.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women's Health and Nephrology/Medical.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the period ended June 30, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... , ... “Tomorrow Trump Goes To Washington”: a brief but engaging illustration ... to America. “Tomorrow Trump Goes To Washington” is the creation of published author, Nancy ... country. , Nancy attributes her patriotic nature to her WWII veteran father. She ...
(Date:12/7/2016)... ... 2016 , ... Dr. Greg Leyer, the Chief Scientific Officer ... DC workshop on November 2nd. The conference was an opportunity for both probiotic ... regulations. , Dr. Leyer spoke about two main topics at the IPA ...
(Date:12/6/2016)... ... December 06, 2016 , ... Men with gum disease ... of serious health problems, such as cardiovascular illness, according to research cited in ... Hills Periodontics & Dental Implant Center notes that the correlation between periodontal disease ...
(Date:12/6/2016)... TX (PRWEB) , ... December ... ... in predictive and prescriptive health insights for population health management, announces today ... provider. VitreosHealth will leverage CitiusTech’s cloud-hosted clinical rules engine that offers advanced ...
(Date:12/6/2016)... ON (PRWEB) , ... December 06, 2016 , ... CarriersEdge, ... today announced a new suite of Driver Wellness courses. Offered in three modules, the ... a starting point so fleets can educate drivers about how to stay healthy on ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... 6, 2016 Eurofins Genomics today announced ... College of American Pathologists (CAP) and certification under ... new laboratory in Louisville, KY ... American headquarters. "Our new CLIA-licensed and ... is still considered the ,Gold Standard, method for ...
(Date:12/6/2016)... Dec. 6, 2016 Two new disaster drones ... a simulated mass casualty event Tuesday at John Bell ... technology debuted before an audience including Mississippi ... from Homeland Security, Federal Law Enforcement Agencies, and the ... as HiRO (Health Integrated Rescue Operations), was developed by ...
(Date:12/6/2016)... 6, 2016  Arcturus Therapeutics, Inc. ("Arcturus" or ... today that it entered into collaboration with Takeda ... the treatment of NASH and other gastrointestinal (GI) ... LUNAR™ and UNA Oligomer chemistry. The financial terms ... commitment to and expertise in GI disorders, we ...
Breaking Medicine Technology: